Skip to main content
Journal cover image

Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.

Journal articles  - Journal Article
Rothman, AL; Beca, FA; Tijerina, JD; Schuman, DM; Parrish, RK; Vanner, EA; Liu, KC
Published in: Ophthalmol Glaucoma
2024

PURPOSE: To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF. DESIGN: Retrospective clinical cohort study. PARTICIPANTS: Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded. METHODS: A Kaplan-Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years. MAIN OUTCOME MEASURES: Survival analysis, IOP, number of medications. RESULTS: Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (P = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (P = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, P = 0.05), greater IOP reduction (60% vs. 49%, P = 0.04), fewer medications (1.2 vs. 2.1, P = 0.02), and more complete success (50% vs. 15%, P = 0.001) at final follow-up (32 vs. 36 months, P = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], P = 0.04). There were no significant differences in early or late complications. CONCLUSIONS: Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmol Glaucoma

DOI

EISSN

2589-4196

Publication Date

2024

Volume

7

Issue

3

Start / End Page

260 / 270

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Retrospective Studies
  • Ranibizumab
  • Male
  • Intravitreal Injections
  • Intraocular Pressure
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rothman, A. L., Beca, F. A., Tijerina, J. D., Schuman, D. M., Parrish, R. K., Vanner, E. A., & Liu, K. C. (2024). Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma, 7(3), 260–270. https://doi.org/10.1016/j.ogla.2024.01.002
Rothman, Adam L., Flavius A. Beca, Jonathan D. Tijerina, Darren M. Schuman, Richard K. Parrish, Elizabeth A. Vanner, and Katy C. Liu. “Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.” Ophthalmol Glaucoma 7, no. 3 (2024): 260–70. https://doi.org/10.1016/j.ogla.2024.01.002.
Rothman AL, Beca FA, Tijerina JD, Schuman DM, Parrish RK, Vanner EA, et al. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma. 2024;7(3):260–70.
Rothman, Adam L., et al. “Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.” Ophthalmol Glaucoma, vol. 7, no. 3, 2024, pp. 260–70. Pubmed, doi:10.1016/j.ogla.2024.01.002.
Rothman AL, Beca FA, Tijerina JD, Schuman DM, Parrish RK, Vanner EA, Liu KC. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration. Ophthalmol Glaucoma. 2024;7(3):260–270.
Journal cover image

Published In

Ophthalmol Glaucoma

DOI

EISSN

2589-4196

Publication Date

2024

Volume

7

Issue

3

Start / End Page

260 / 270

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Retrospective Studies
  • Ranibizumab
  • Male
  • Intravitreal Injections
  • Intraocular Pressure
  • Humans